Frontlight ResearchEarly access
Prostate cancer trials in Japan
41 of 43 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Where
- Chuo Ku, Koto-ku
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07730021 · EU 2026-525938-31-00 - Phase 1Active, not recruitingA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Kashiwa
- Age
- 18 years and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - Phase 3Taking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Akita, Asahikawa, Fukuoka, Fukushima, Gifu, Hirakata, Hiroshima, Kagoshima, Kashihara, Kita, Kitakyushu, Kobe, Kumamoto, Kurume, Minato, Miyazaki, Mukai-awagasaki, Nagano, Ōita, Ōmura, Saga, Sakai, Sakura, Sapporo, Shimajiri, Suita, Tōon, Yokohama
- Age
- 18 years and over
- People
- 1,310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - Phase 1Taking peopleStudy of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Kashiwa-shi, Koto-ku, Yokohama
- Age
- 18 years and over
- People
- 505 worldwide
- Run by
- Amgen
See details and how to joinNCT04221542 · EU 2023-504361-23-00 - Phase 2Active, not recruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Where
- Kashiwa
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Pfizer
See details and how to joinNCT04557449 · EU 2024-512120-11-00 - Phase 1/2Taking peopleFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
- Where
- Tokyo
- Age
- 18 years and over
- People
- 54 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07332455 - Phase 3Taking peopleDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- Where
- Osaka, Tokyo
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- ABX advanced biochemical compounds GmbH
See details and how to joinNCT06122584 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Chūōku, Kashiwa, Chiba, Kōtō City, Nagoya
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 1Enrolling by invitationA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Nagoya, Tokyo
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 1Not yet taking people in JapanA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Chiba, Kyoto, Osaka
- Age
- 18 years and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - Phase 1Taking peopleA Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
- Where
- Tokyo
- Age
- 18 years and over
- People
- 355 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06095089 · EU 2023-504063-17-00 - Phase 3Taking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama, Meguro-Ku, Sakura, Sapporo, Yokohama, Yokosuka
- Age
- 18 years and over
- People
- 1,203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - Phase 3Taking peopleA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Bunkyō City, Hirakata, Kanazawa, Kobe, Sagamihara, Sunto-gun, Yokohama
- Age
- 18 years and over
- People
- 800 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00 - Phase 2Taking peopleA Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- Where
- Kobe
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07832292 - Phase 3Active, not recruitingA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Chiba, Fukuoka, Kanazawa, Kashiwa, Kobe, Kumamoto, Matsuyama, Osaka, Sapporo, Shinjuku-ku, Suita, Yamagata, Yokohama, Yokosuka
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - Phase 3Taking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Chūō, Fukuoka, Gifu, Ginowan, Hamamatsu, Hiroshima, Kagoshima, Kahoku-gun, Kamakura, Kitakyushu, Kobe, Koshigaya, Kumamoto, Kurume, Kyoto, Minato, Nagano, Nagasaki, Nagoya, Niigata, Sakai, Sakura, Sapporo, Shinjuku, Tokushima, Tōon, Ube, Yufu
- Age
- 18 years and over
- People
- 1,440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - Phase 1/2Taking peopleStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Where
- Kyoto
- Age
- 18 years and over
- People
- 205 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07288359 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1Taking peopleA Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Where
- Kashiwa-shi, Kobe, Kōtoku, Sakura-shi
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07244341 · EU 2025-522512-16-00 - Phase 1Taking peopleA Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Where
- Hirakata
- Age
- 18 years and over
- People
- 208 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07570979 - Phase 1/2Taking peopleStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Chūōku, Kashiwa, Kōtoku
- Age
- 18 years to 130 years
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - Phase 2Taking peopleStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Where
- Chuo Ku, Kashiwa, Nagoya, Yokohama
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Pfizer
See details and how to joinNCT04606446 - Phase 3Taking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Chuo Ku, Fukuoka, Fukushima, Ishikawa, Kashiwa, Kobe, Kyoto, Sapporo, Yokohama
- Age
- 18 years to 100 years
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00 - Phase 3Taking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Akita, Eiheiji-cho,Yoshida-gun, Fukuoka, Fukushima, Gifu, Hirakata, Hiroshima, Kagoshima, Kashihara, Kita, Kitakyushu, Kobe, Kumamoto, Minato, Miyazaki, Mukai-awagasaki, Nagano, Ōita, Ōmura, Saga, Sakai, Sakura, Sapporo, Shimajiri, Suita, tabashi City, Tsu, Yokohama
- Age
- 18 years and over
- People
- 1,314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - Phase 3Taking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Bunkyo-ku, Fukuoka, Hidaka-shi, Kanazawa, Kita-gun, Kobe, Koshigaya-shi, Koto-ku, Matsuyama, Minato-ku, Nagoya, Osaka, Sagamihara-shi, Suita-shi, Toyama
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674